{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.1","upperLimit":"26.1","value":"20.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"}],"units":"Participants"}],"title":"All treated participants"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.8","upperLimit":"23.5","value":"16.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"}],"units":"Participants"}],"title":"PD-L1 <1%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.4","upperLimit":"34.4","value":"25.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"}],"units":"Participants"}],"title":"PD-L1 >= 1%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.1","upperLimit":"22.1","value":"16.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"}],"units":"Participants"}],"title":"PD-L1 <5%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.6","upperLimit":"42.4","value":"31.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"}],"units":"Participants"}],"title":"PD-L1 >=5%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"}],"units":"Participants"}],"description":"Objective Response Rate (ORR) was defined as the percent of participants with a best overall response of confirmed Complete Response (CR) or Partial Response (PR) (per RECIST 1.1 criteria). RECIST 1.1 = Response Evaluation Criteria in Solid Tumors. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. BIRC= blinded independent review committee PD-L1 expression level= membranous staining in greater than or equal to 5% and greater than or equal to 1% tumor cells.\n\nNote: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date.\"","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg was administered as a 60 minute IV infusion Q2W","id":"OG000","title":"Nivolumab 3 mg/kg"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From the date of first dose to the date of objectively documented progression or the date of subsequent therapy, whichever occurs first (up approximately to 43 months)","title":"Objective Response Rate (ORR) Per BIRC Assessment - Extended Collection","type":"POST_HOC","unitOfMeasure":"Percent of Participants"}